Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2016

Dec 31, 2016

33483_dirs_2016-12-30_3d484cdb-e717-43c6-aaec-bc3a10fab36f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-12-28

Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-12-28 Common Stock M 10000 $2.77 Acquired 10000 Direct
2016-12-28 Common Stock S 10000 $17.55 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-12-28 Employee Stock Option (right to buy) $2.77 M 10000 Disposed 2021-09-07 Common Stock (10000) Direct

Footnotes

F1: The shares underlying the option are fully vested.